Mundipharma Partners With Samsung Bioepis For Hong Kong And Taiwan
Partnership Covers Adalimumab, Etanercept, Trastuzumab and Bevacizumab
• By Akriti Seth
Samsung Bioepis chooses Mundipharma to commercialize its first-wave biosimilar candidates in Taiwan and Hong Kong • Source: Shutterstock 
